Journal Watch · Cell Metabolism · 2026
Gut enteroendocrine cell activation using a combination of GPR119 and GPR40 agonists results in synergistic hormone secretion in mice and humans.
The levels of circulating gut hormones observed in phase 1 trials exceeded levels observed in bariatric surgery, warranting further clinical investigation of these compounds for weight loss and glucose control.
TL;DR
The levels of circulating gut hormones observed in phase 1 trials exceeded levels observed in bariatric surgery, warranting further clinical investigation of these compounds for weight loss and glucose control.
Key findings
- The combination was efficacious in improving glucose tolerance and promoting weight loss in mice.
- The levels of circulating gut hormones observed in phase 1 trials exceeded levels observed in bariatric surgery, warranting further clinical investigation of these compounds for weight loss and glucose control.
What they did
Advanced technologies were used to obtain a comprehensive understanding of EEC diversity, resulting in the identification of cells that express both satiety hormones and target receptors, including GPR40 (FFAR1) and GPR119. We developed gut-targeted agonists of these receptors, K-757 and K-833, and demonstrated synergistic hormone secretion in murine and human enteroids.
Full abstract (original)
Background: A leading hypothesis for the effectiveness of bariatric surgery for weight loss is supraphysiologic activation of gut enteroendocrine cells (EECs), which results in elevated postprandial levels of satiety hormones, including glucagon-like peptide-1 (GLP-1). Here, we describe direct targeting of EECs to mimic effects of bariatric surgery.
What they did: Advanced technologies were used to obtain a comprehensive understanding of EEC diversity, resulting in the identification of cells that express both satiety hormones and target receptors, including GPR40 (FFAR1) and GPR119. We developed gut-targeted agonists of these receptors, K-757 and K-833, and demonstrated synergistic hormone secretion in murine and human enteroids.
Results & conclusions: The combination was efficacious in improving glucose tolerance and promoting weight loss in mice. The levels of circulating gut hormones observed in phase 1 trials exceeded levels observed in bariatric surgery, warranting further clinical investigation of these compounds for weight loss and glucose control.
Abstract © the authors / Cell Metabolism (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cmet.2025.11.001 · PubMed 41338185.
Why it matters for pharma & biotech
- Directly relevant to teams in metabolic / GLP-1 therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: metabolic / GLP-1 therapeutics · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Cell Metabolism study find?
The levels of circulating gut hormones observed in phase 1 trials exceeded levels observed in bariatric surgery, warranting further clinical investigation of these compounds for weight loss and glucose control.
What type of study is this?
It is a randomised / controlled clinical trial, published in Cell Metabolism in 2026. Advanced technologies were used to obtain a comprehensive understanding of EEC diversity, resulting in the identification of cells that express both satiety hormones and target receptors, including GPR40 (FFAR1) and GPR119.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.cmet.2025.11.001. PubMed ID: 41338185. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/gut-enteroendocrine-cell-activation-using-a-combination-of-gpr119-and-gp-511001/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides